Levetiracetam
Product Images NDC 70518-0554

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 70518-0554). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Levetiracetam 500 mg tablet label showing a package quantity of 30 tablets. The label includes the NDC number 70518-0554-00, manufacturing details for Camber Pharma, Inc., and repackaging information for RemedyRepack Inc. Storage instructions are also displayed. The label features branding for RemedyRepack in purple.*

FDA Label Image

Levetiracetamtabletsfigure1

A bar chart comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The chart shows patient percentages on the vertical axis and treatment groups on the horizontal axis, with Levetiracetam groups having higher percentages than placebo.*

FDA Label Image

Levetiracetamtabletsfigure2

A bar chart showing the percentage of patients by treatment group: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The chart compares patient response rates, with the highest percentage observed in the Levetiracetam 2000 mg/day group.*

FDA Label Image

Levetiracetamtabletsfigure3

A bar graph comparing the percentage of patients between two groups: Placebo (N=104) and Levetiracetam 3000 mg/day (N=180). The y-axis shows the percentage of patients from 0% to 45%. The Levetiracetam group has a higher percentage (39.4%) compared to the Placebo group (14.4%).*

FDA Label Image

Levetiracetamtabletsfigure4

A bar chart comparing the percentage of patients between Placebo (N=97) and Levetiracetam (N=101). The chart shows 19.6% for Placebo and 44.6% for Levetiracetam on the vertical axis labeled '% of Patients.'*

FDA Label Image

Levetiracetamtabletsfigure5

Bar chart comparing the percentage of patients between placebo and levetiracetam groups. The placebo group (N=51) shows 19.6% of patients, while the levetiracetam group (N=58) shows 43.1%. The y-axis represents the percentage of patients, ranging from 0% to 45%.*

FDA Label Image

Levetiracetamtabletsfigure6

A bar chart comparing the percentage of patients between Placebo (N=84) and Levetiracetam (N=79) groups. The y-axis represents the percentage of patients from 0% to 100%. The Placebo group has a value of 45.2%, while the Levetiracetam group shows a higher value of 72.2% with an asterisk above it.*

FDA Label Image

Levetiracetamtabletsstructure

Chemical structure of levetiracetam showing a pyrrolidone ring attached to an ethyl group and an amide functional group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.